About
I am a Wellcome Early Career Fellow (https://www.liverpool.ac.uk/researcher/news/articles/early-career-researcher-receives-five-year-wellcome-award-for-adenovirus-research) based in the Department of Pharmacology and Therapeutics (ISMIB) at the University of Liverpool. My research programme aims to improve the safety and efficacy of viral vector-based vaccines and therapies that will underpin the development of next generation adenoviral-based vectors with applications for infectious diseases, gene therapy and cancer therapy.
Prior to starting my own research group, I was a Postdoctoral Research Associate (2022-2025) in the Immunopharmacology research group at the University of Liverpool. This Medical Research Council (MRC) funded role focused on the study of T-cell mediated allergies to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapies, with the aim of developing a personalised treatment approach for these new, transformative modulators. I received my PhD (2022) from the University of Liverpool where I investigated the immunogenicity of glycopeptide antibiotics, such as vancomycin, in patients diagnosed with severe cutaneous adverse reactions (SCAR).
Work in my group is currently funded by a Wellcome Early Career award (https://wellcome.org/research-funding/funding-portfolio/funded-grants/investigating-impact-pre-existing-adenovirus).